Abstract: The disclosure relates to nucleic acids having Apoptotic Sequence Nos. 5, 8, 9, 11, 14, 60 and 66. It also relates to agents targeting Apoptotic Sequences, said agents having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ ID NO:7. The composition may also include a pharmaceutically acceptable carrier. The disclosure also includes a method of killing a cancer cell by administering to a cancer cell a treatment formulation including a nucleic acid having an Apoptotic Sequence targeting agent of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ ID NO:7 and a pharmaceutically acceptable carrier. The cancer cell may be located in a subject with cancer.

Abstract: Cancer detection reagents have been identified through comparison of cancer mRNAs with the transcriptome of healthy cells. These cancer detection reagents may be used for a variety of purposes including diagnostics and targeted destruction of cancer cells. In diagnostic applications, peripheral blood or other tissue samples from a subject may be analyzed to generate a cancer profile for that subject. That profile may then be used to guide cancer treatment with known agents. It may also be used to generate agents capable of killing the subject's cancer cells in a targeted manner. These agents may include antibodies and siRNA, RNAi, or antisense RNA.

Abstract: The present invention relates to cancer markers and methods of detecting cancer markers in a sample. The sample may be peripheral blood. Cancer markers are most commonly mutated or abnormal DNA sequences associated with metastatic cancer. Markers may be detected using PCR, microarrays, or other nucleic acid or peptide-based assays. These methods may be used for a variety of diagnostic purposes, including initial, early-stage or later diagnosis of cancer, particularly metastatic cancer and monitoring of cancer or treatment progression. The cancer markers may also be used to create a cancer marker profile. Treatment may be directed based on this profile. Additionally, methods using blood may provide a cancer marker profile of mutations or abnormalities found in at least one of several tumors in the body, instead of merely one tumor. The invention also include kits, such as primer kits, and microarrays for use in performing the various methods.

Abstract: The disclosure relates to a nucleic acid having an Apoptotic Sequence of: Seq. ID. No:1, Seq. ID. No:2, Seq. ID. No:3, Seq. ID. No:4, Seq. ID. No: 5, Seq. ID. No:6, and Seq. ID. No:7. It also relates to a compsoition including a nucleic acid having an Apoptotic Sequence of Seq. ID. No:1, Seq. ID. No:2, Seq. ID. No:3, Seq. ID. No:4, Seq. ID. No: 5, Seq. ID. No:6, and Seq. ID. No:7. The composition may also include a pharmaceutically acceptable carrier. The disclosure also includes a method of killing a cancer cell by administering to a cancer cell a serum including a nucleic acid having an Apoptotic Sequence of: Seq. ID. No:1, Seq. ID. No:2, Seq. ID. No:3, Seq. ID. No:4, Seq. ID. No: 5, Seq. ID. No:6, and Seq. ID. No:7 and a pharmaceutically acceptable carrier. The cancer cell may be located in a subject with cancer.